Genomic analyses reveal broad impact of miR-137 on genes associated with malignant transformation and neuronal differentiation in glioblastoma cells

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Tamim, Saleh ^a   Vo, Dat T ^a   Uren, Philip J ^b   Qiao, Mei ^a   Bindewald, Eckart ^c   Kasprzak, Wojciech K ^c   Shapiro, Bruce A ^d,e   Nakaya, Helder I ^f   Burns, Suzanne C ^a   Araujo, Patricia R ^a   Nakano, Ichiro ^g   Radek, Agnes J ^h   Kuersten, Scott ^h   Smith, Andrew D ^b   Penalva, Luiz O F ^a,i  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c SAIC FREDERICK INC   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e Center for Cancer Research Nanobiology Program National Cancer Institute   (United States)

^f UNIVERSITY OF SÃO PAULO   (Brazil)

^g OHIO STATE UNIVERSITY   (United States)

^h ILLUMINA INC   (United States)

ⁱ University of Texas Health Science Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD24 ANTIGEN; CYCLIN DEPENDENT KINASE 6; MESSENGER RNA; MICRORNA; MICRORNA 124; MICRORNA 128; MICRORNA 137; MICRORNA 7; POLYADENYLIC ACID BINDING PROTEIN; PROTEIN CDC42; PROTEIN KINASE B BETA; STEM CELL FACTOR RECEPTOR; TRANSFORMING GROWTH FACTOR BETA2; UNCLASSIFIED DRUG; Y BOX BINDING PROTEIN 1; MIRN137 MICRORNA, HUMAN; TUMOR PROTEIN;

AKT2 GENE; APOPTOSIS; ARTICLE; C KIT GEN; CD24 GENE; CDC42 GENE; CDK6 GENE; CELL PROLIFERATION; CONTROLLED STUDY; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENOME ANALYSIS; GLIOBLASTOMA; MALIGNANT TRANSFORMATION; MSI1 GENE; MTDH GENE; NERVE CELL DIFFERENTIATION; NERVOUS SYSTEM DEVELOPMENT; NEURAL STEM CELL; NUCLEOTIDE SEQUENCE; ONCOGENE; RNA SEQUENCE; TGF BETA2 GENE; YBX1 GENE; BIOLOGICAL MODEL; BRAIN TUMOR; CELL DIFFERENTIATION; CELL MOTION; CELL TRANSFORMATION; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; GENETIC PREDISPOSITION; GENETICS; HUMAN; METABOLISM; NERVE CELL; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

APOPTOSIS; BLOTTING, WESTERN; BRAIN NEOPLASMS; CELL DIFFERENTIATION; CELL MOVEMENT; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; GLIOBLASTOMA; HUMANS; MICRORNAS; MODELS, GENETIC; NEOPLASM PROTEINS; NEUROGENESIS; NEURONS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84899835835     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0085591     Document Type: Article

References (104)

1. Kim TM, Huang W, Park R, Park PJ, Johnson MD (2011) A developmental taxonomy of glioblastoma defined and maintained by MicroRNAs. Cancer Res 71: 3387-3399.
2. Sumazin P, Yang X, Chiu HS, Chung WJ, Iyer A, et al. (2011) An extensive microRNA-mediated network of RNA-RNA interactions regulates established oncogenic pathways in glioblastoma. Cell 147: 370-381.
3. Setty M, Helmy K, Khan AA, Silber J, Arvey A, et al. (2012) Inferring transcriptional and microRNA-mediated regulatory programs in glioblastoma. Mol Syst Biol 8: 605.
4. Gonzalez-Gomez P, Sanchez P, Mira H (2011) MicroRNAs as regulators of neural stem cell-related pathways in glioblastoma multiforme. Mol Neurobiol 44: 235-249.
5. Perruisseau-Carrier C, Jurga M, Forraz N, McGuckin CP (2011) miRNAs stem cell reprogramming for neuronal induction and differentiation. Mol Neurobiol 43: 215-227.
6. Silber J, Lim DA, Petritsch C, Persson AI, Maunakea AK, et al. (2008) miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. BMC Med 6: 14.
7. Smrt RD, Szulwach KE, Pfeiffer RL, Li X, Guo W, et al. (2010) MicroRNA miR-137 regulates neuronal maturation by targeting ubiquitin ligase mind bomb-1. Stem Cells 28: 1060-1070.
8. Tarantino C, Paolella G, Cozzuto L, Minopoli G, Pastore L, et al. (2010) miRNA 34a, 100, and 137 modulate differentiation of mouse embryonic stem cells. FASEB J 24: 3255-3263.
9. Vo DT, Qiao M, Smith AD, Burns SC, Brenner AJ, et al. (2011) The oncogenic RNA-binding protein Musashi1 is regulated by tumor suppressor miRNAs. RNA Biol 8: 817-828.
10. Sun G, Ye P, Murai K, Lang MF, Li S, et al. (2011) miR-137 forms a regulatory loop with nuclear receptor TLX and LSD1 in neural stem cells. Nat Commun 2: 529.
11. Chen L, Wang X, Wang H, Li Y, Yan W, et al. (2012) miR-137 is frequently down-regulated in glioblastoma and is a negative regulator of Cox-2. Eur J Cancer 48: 3104-3111.
12. Li KK, Yang L, Pang JC, Chan AK, Zhou L, et al. (2012) MIR-137 Suppresses Growth and Invasion, is Downregulated in Oligodendroglial Tumors and Targets CSE1L. Brain Pathol.
13. Bier A, Giladi N, Kronfeld N, Lee HK, Cazacu S, et al. (2013) MicroRNA-137 is downregulated in glioblastoma and inhibits the stemness of glioma stem cells by targeting RTVP-1. Oncotarget 4: 665-676.
14. Balaguer F, Link A, Lozano JJ, Cuatrecasas M, Nagasaka T, et al. (2010) Epigenetic silencing of miR-137 is an early event in colorectal carcinogenesis. Cancer Res 70: 6609-6618.
15. Kozaki K, Imoto I, Mogi S, Omura K, Inazawa J (2008) Exploration of tumorsuppressive microRNAs silenced by DNA hypermethylation in oral cancer. Cancer Res 68: 2094-2105. (Pubitemid 351521781)
16. Chen Q, Chen X, Zhang M, Fan Q, Luo S, et al. (2011) miR-137 is frequently down-regulated in gastric cancer and is a negative regulator of Cdc42. Dig Dis Sci 56: 2009-2016.
17. Langevin SM, Stone RA, Bunker CH, Grandis JR, Sobol RW, et al. (2010) MicroRNA-137 promoter methylation in oral rinses from patients with squamous cell carcinoma of the head and neck is associated with gender and body mass index. Carcinogenesis 31: 864-870.
18. Langevin SM, Stone RA, Bunker CH, Lyons-Weiler MA, LaFramboise WA, et al. (2011) MicroRNA-137 promoter methylation is associated with poorer overall survival in patients with squamous cell carcinoma of the head and neck. Cancer 117: 1454-1462.
19. Chen X, Wang J, Shen H, Lu J, Li C, et al. (2011) Epigenetics, microRNAs, and carcinogenesis: functional role of microRNA-137 in uveal melanoma. Invest Ophthalmol Vis Sci 52: 1193-1199.
20. Zhao Y, Li Y, Lou G, Zhao L, Xu Z, et al. (2012) MiR-137 targets estrogen-related receptor alpha and impairs the proliferative and migratory capacity of breast cancer cells. PLoS One 7: e39102.
21. Zhu X, Shen H, Li H, Long L, Hui L, et al. (2012) miR-137 inhibits the proliferation of lung cancer cells by targeting Cdc42 and Cdk6. FEBS Lett.
22. Althoff K, Beckers A, Odersky A, Mestdagh P, Koster J, et al. (2013) MiR-137 functions as a tumor suppressor in neuroblastoma by downregulating KDM1A. Int J Cancer 133: 1064-1073.
23. Szulwach KE, Li X, Smrt RD, Li Y, Luo Y, et al. (2010) Cross talk between microRNA and epigenetic regulation in adult neurogenesis. J Cell Biol 189: 127-141.
24. Moretti F, Kaiser C, Zdanowicz-Specht A, Hentze MW (2012) PABP and the poly(A) tail augment microRNA repression by facilitated miRISC binding. Nat Struct Mol Biol 19: 603-608.
25. Fabian MR, Sonenberg N (2012) The mechanics of miRNA-mediated gene silencing: a look under the hood of miRISC. Nat Struct Mol Biol 19: 586-593.
26. Penalva LO, Keene JD (2004) Biotinylated tags for recovery and characterization of ribonucleoprotein complexes. Biotechniques 37: 604, 606, 608-610.
27. Jain R, Devine T, George AD, Chittur SV, Baroni TE, et al. (2011) RIP-Chip analysis: RNA-Binding Protein Immunoprecipitation-Microarray (Chip) Profiling. Methods Mol Biol 703: 247-263.
28. Smith AD, Chung WY, Hodges E, Kendall J, Hannon G, et al. (2009) Updates to the RMAP short-read mapping software. Bioinformatics 25: 2841-2842.
29. Benjamini Y, Hochberg Y (1995) Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society Series B (Methodological) 57: 289-300.
30. Lewis BP, Burge CB, Bartel DP (2005) Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120: 15-20. (Pubitemid 40094598)
31. Betel D, Wilson M, Gabow A, Marks DS, Sander C (2008) The microRNA.org resource: targets and expression. Nucleic Acids Res 36: D149-153. (Pubitemid 351149712)
32. Chen K, Rajewsky N (2006) Natural selection on human microRNA binding sites inferred from SNP data. Nat Genet 38: 1452-1456. (Pubitemid 44837570)
33. Huang da W, Sherman BT, Lempicki RA (2009) Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 37: 1-13.
34. Huang da W, Sherman BT, Lempicki RA (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44-57.
35. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, et al. (2012) The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2: 401-404.
36. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, et al. (2013) Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6: pl1.
37. Kertesz M, Iovino N, Unnerstall U, Gaul U, Segal E (2007) The role of site accessibility in microRNA target recognition. Nat Genet 39: 1278-1284. (Pubitemid 47482690)
38. Lorenz R, Bernhart SH, Honer Zu Siederdissen C, Tafer H, Flamm C, et al. (2011) ViennaRNA Package 2.0. Algorithms Mol Biol 6: 26.
39. Baek D, Villen J, Shin C, Camargo FD, Gygi SP, et al. (2008) The impact of microRNAs on protein output. Nature 455: 64-71.
40. Chi SW, Zang JB, Mele A, Darnell RB (2009) Argonaute HITS-CLIP decodes microRNA-mRNA interaction maps. Nature 460: 479-486.
41. Hendrickson DG, Hogan DJ, Herschlag D, Ferrell JE, Brown PO (2008) Systematic identification of mRNAs recruited to argonaute 2 by specific microRNAs and corresponding changes in transcript abundance. PLoS One 3: e2126.
42. Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, et al. (2005) Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 433: 769-773. (Pubitemid 40292988)
43. Selbach M, Schwanhausser B, Thierfelder N, Fang Z, Khanin R, et al. (2008) Widespread changes in protein synthesis induced by microRNAs. Nature 455: 58-63.
44. Boutz DR, Collins PJ, Suresh U, Lu M, Ramirez CM, et al. (2011) Two-tiered approach identifies a network of cancer and liver disease-related genes regulated by miR-122. J Biol Chem 286: 18066-18078.
45. Li B, He H, Tao BB, Zhao ZY, Hu GH, et al. (2012) Knockdown of CDK6 enhances glioma sensitivity to chemotherapy. Oncol Rep 28: 909-914.
46. Cole MF, Johnstone SE, Newman JJ, Kagey MH, Young RA (2008) Tcf3 is an integral component of the core regulatory circuitry of embryonic stem cells. Genes Dev 22: 746-755. (Pubitemid 351439106)
47. Nagamine T, Shimomura S, Sueyoshi N, Kameshita I (2011) Influence of Ser/Pro-rich domain and kinase domain of double cortin-like protein kinase on microtubule-binding activity. J Biochem 149: 619-627.
48. Shu T, Tseng HC, Sapir T, Stern P, Zhou Y, et al. (2006) Doublecortin-like kinase controls neurogenesis by regulating mitotic spindles and M phase progression. Neuron 49: 25-39. (Pubitemid 43017183)
49. Fitzsimons CP, Ahmed S, Wittevrongel CF, Schouten TG, Dijkmans TF, et al. (2008) The microtubule-associated protein doublecortin-like regulates the transport of the glucocorticoid receptor in neuronal progenitor cells. Mol Endocrinol 22: 248-262. (Pubitemid 351185929)
50. Saaltink DJ, Havik B, Verissimo CS, Lucassen PJ, Vreugdenhil E (2012) Doublecortin and doublecortin-like are expressed in overlapping and non-overlapping neuronal cell population: implications for neurogenesis. J Comp Neurol 520: 2805-2823.
51. Verissimo CS, Molenaar JJ, Meerman J, Puigvert JC, Lamers F, et al. (2010) Silencing of the microtubule-associated proteins doublecortin-like and doublecortin-like kinase-long induces apoptosis in neuroblastoma cells. Endocr Relat Cancer 17: 399-414.
52. Song R, Kim YW, Koo BK, Jeong HW, Yoon MJ, et al. (2008) Mind bomb 1 in the lymphopoietic niches is essential for T and marginal zone B cell development. J Exp Med 205: 2525-2536.
53. Kang K, Lee D, Hong S, Park SG, Song MR (2012) The E3 ligase mindbomb-1 (Mib1) modulates Delta-Notch signaling to control neurogenesis and gliogenesis in the developing spinal cord. J Biol Chem.
54. Sharma S, Saboorian HM, Frawley WH, Frenkel EP, Haley BB, et al. (2004) MIB1 labeling index as an indicator of chemoresponse in carcinoma of the breast. Appl Immunohistochem Mol Morphol 12: 290-295. (Pubitemid 39602067)
55. O'Neill CJ, Deavers MT, Malpica A, Foster H, McCluggage WG (2005) An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms. Am J Surg Pathol 29: 1034-1041. (Pubitemid 41045547)
56. Quintero A, Alvarez-Kindelan J, Luque RJ, Gonzalez-Campora R, Requena MJ, et al. (2006) Ki-67 MIB1 labelling index and the prognosis of primary TaT1 urothelial cell carcinoma of the bladder. J Clin Pathol 59: 83-88. (Pubitemid 43076244)
57. Schmitt A, Saremaslani P, Schmid S, Rousson V, Montani M, et al. (2006) IGFII and MIB1 immunohistochemistry is helpful for the differentiation of benign from malignant adrenocortical tumours. Histopathology 49: 298-307. (Pubitemid 44253620)
58. Aleskandarany MA, Rakha EA, Macmillan RD, Powe DG, Ellis IO, et al. (2011) MIB1/Ki-67 labelling index can classify grade 2 breast cancer into two clinically distinct subgroups. Breast Cancer Res Treat 127: 591-599.
59. Berndt JD, Aoyagi A, Yang P, Anastas JN, Tang L, et al. (2011) Mindbomb 1, an E3 ubiquitin ligase, forms a complex with RYK to activate Wnt/beta-catenin signaling. J Cell Biol 194: 737-750.
60. Ch'ng ES, Kumanogoh A (2010) Roles of Sema4D and Plexin-B1 in tumor progression. Mol Cancer 9: 251.
61. Kelleher FC, McArthur GA (2012) Targeting NRAS in melanoma. Cancer J 18: 132-136.
62. Ahluwalia MS, de Groot J, Liu WM, Gladson CL (2010) Targeting SRC in glioblastoma tumors and brain metastases: rationale and preclinical studies. Cancer Lett 298: 139-149.
63. Lu KV, Zhu S, Cvrljevic A, Huang TT, Sarkaria S, et al. (2009) Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients. Cancer Res 69: 6889-6898.
64. Milano V, Piao Y, LaFortune T, de Groot J (2009) Dasatinib-induced autophagy is enhanced in combination with temozolomide in glioma. Mol Cancer Ther 8: 394-406.
65. Huveldt D, Lewis-Tuffin LJ, Carlson BL, Schroeder MA, Rodriguez F, et al. (2013) Targeting Src family kinases inhibits bevacizumab-induced glioma cell invasion. PLoS One 8: e56505.
66. Nielsen S, Nagelhus EA, Amiry-Moghaddam M, Bourque C, Agre P, et al. (1997) Specialized membrane domains for water transport in glial cells: high-resolution immunogold cytochemistry of aquaporin-4 in rat brain. J Neurosci 17: 171-180. (Pubitemid 27008860)
67. Warth A, Simon P, Capper D, Goeppert B, Tabatabai G, et al. (2007) Expression pattern of the water channel aquaporin-4 in human gliomas is associated with blood-brain barrier disturbance but not with patient survival. J Neurosci Res 85: 1336-1346. (Pubitemid 46724376)
68. Saadoun S, Papadopoulos MC, Watanabe H, Yan D, Manley GT, et al. (2005) Involvement of aquaporin-4 in astroglial cell migration and glial scar formation. J Cell Sci 118: 5691-5698. (Pubitemid 43079263)
69. Badaut J, Lasbennes F, Magistretti PJ, Regli L (2002) Aquaporins in brain: distribution, physiology, and pathophysiology. J Cereb Blood Flow Metab 22: 367-378. (Pubitemid 34273593)
70. Featherstone DE (2011) Glial solute carrier transporters in Drosophila and mice. Glia 59: 1351-1363.
71. Kwon E, Wang W, Tsai LH (2011) Validation of schizophrenia-associated genes CSMD1, C10orf26, CACNA1C and TCF4 as miR-137 targets. Mol Psychiatry.
72. Glazer RI, Vo DT, Penalva LO (2012) Musashi1: an RBP with versatile functions in normal and cancer stem cells. Front Biosci 17: 54-64.
73. Peter ME (2010) Targeting of mRNAs by multiple miRNAs: the next step. Oncogene 29: 2161-2164.
74. Xu J, Li CX, Li YS, Lv JY, Ma Y, et al. (2011) MiRNA-miRNA synergistic network: construction via co-regulating functional modules and disease miRNA topological features. Nucleic Acids Res 39: 825-836.
75. Bader AG, Brown D, Winkler M (2010) The promise of microRNA replacement therapy. Cancer Res 70: 7027-7030.
76. Garofalo M, Croce CM (2011) microRNAs: Master regulators as potential therapeutics in cancer. Annu Rev Pharmacol Toxicol 51: 25-43.
77. Henry JC, Azevedo-Pouly AC, Schmittgen TD (2011) MicroRNA replacement therapy for cancer. Pharm Res 28: 3030-3042.
78. Zhang B, Gu F, She C, Guo H, Li W, et al. (2009) Reduction of Akt2 inhibits migration and invasion of glioma cells. Int J Cancer 125: 585-595.
79. Pu P, Kang C, Li J, Jiang H (2004) Antisense and dominant-negative AKT2 cDNA inhibits glioma cell invasion. Tumour Biol 25: 172-178. (Pubitemid 39551743)
80. Zhang J, Han L, Zhang A, Wang Y, Yue X, et al. (2010) AKT2 expression is associated with glioma malignant progression and required for cell survival and invasion. Oncol Rep 24: 65-72.
81. Cui Y, Wang Q, Wang J, Dong Y, Luo C, et al. (2012) Knockdown of AKT2 expression by RNA interference inhibits proliferation, enhances apoptosis, and increases chemosensitivity to the anticancer drug VM-26 in U87 glioma cells. Brain Res 1469: 1-9.
82. Deng J, Gao G, Wang L, Wang T, Yu J, et al. (2012) CD24 expression as a marker for predicting clinical outcome in human gliomas. J Biomed Biotechnol 2012: 517172.
83. Senner V, Sturm A, Baur I, Schrell UH, Distel L, et al. (1999) CD24 promotes invasion of glioma cells in vivo. J Neuropathol Exp Neurol 58: 795-802. (Pubitemid 29372834)
84. Fortin SP, Ennis MJ, Schumacher CA, Zylstra-Diegel CR, Williams BO, et al. (2012) Cdc42 and the guanine nucleotide exchange factors Ect2 and trio mediate Fn14-induced migration and invasion of glioblastoma cells. Mol Cancer Res 10: 958-968.
85. Yiin JJ, Hu B, Jarzynka MJ, Feng H, Liu KW, et al. (2009) Slit2 inhibits glioma cell invasion in the brain by suppression of Cdc42 activity. Neuro Oncol 11: 779-789.
86. Lam PY, Di Tomaso E, Ng HK, Pang JC, Roussel MF, et al. (2000) Expression of p19INK4d, CDK4, CDK6 in glioblastoma multiforme. Br J Neurosurg 14: 28-32. (Pubitemid 30150999)
87. Costello JF, Plass C, Arap W, Chapman VM, Held WA, et al. (1997) Cyclin-dependent kinase 6 (CDK6) amplification in human gliomas identified using two-dimensional separation of genomic DNA. Cancer Res 57: 1250-1254. (Pubitemid 27152546)
88. Gomes AL, Reis-Filho JS, Lopes JM, Martinho O, Lambros MB, et al. (2007) Molecular alterations of KIT oncogene in gliomas. Cell Oncol 29: 399-408. (Pubitemid 47255978)
89. Pittoni P, Piconese S, Tripodo C, Colombo MP (2011) Tumor-intrinsic and - extrinsic roles of c-Kit: mast cells as the primary off-target of tyrosine kinase inhibitors. Oncogene 30: 757-769.
90. Toda M, Iizuka Y, Yu W, Imai T, Ikeda E, et al. (2001) Expression of the neural RNA-binding protein Musashi1 in human gliomas. Glia 34: 1-7. (Pubitemid 32329026)
91. Kanemura Y, Mori K, Sakakibara S, Fujikawa H, Hayashi H, et al. (2001) Musashi1, an evolutionarily conserved neural RNA-binding protein, is a versatile marker of human glioma cells in determining their cellular origin, malignancy, and proliferative activity. Differentiation 68: 141-152. (Pubitemid 34592101)
92. Sanchez-Diaz PC, Burton TL, Burns SC, Hung JY, Penalva LO (2008) Musashi1 modulates cell proliferation genes in the medulloblastoma cell line Daoy. BMC Cancer 8: 280.
93. Vo DT, Subramaniam D, Remke M, Burton TL, Uren PJ, et al. (2012) The RNA-Binding Protein Musashi1 Affects Medulloblastoma Growth via a Network of Cancer-Related Genes and Is an Indicator of Poor Prognosis. Am J Pathol 181: 1762-1772.
94. Vo DT, Abdelmohsen K, Martindale JL, Qiao M, Tominaga K, et al. (2012) The oncogenic RNA-binding protein Musashi1 is regulated by HuR via mRNA translation and stability in glioblastoma cells. Mol Cancer Res 10: 143-155.
95. de Sousa Abreu R, Sanchez-Diaz PC, Vogel C, Burns SC, Ko D, et al. (2009) Genomic analyses of musashi1 downstream targets show a strong association with cancer-related processes. J Biol Chem 284: 12125-12135.
96. Yoo BK, Emdad L, Lee SG, Su ZZ, Santhekadur P, et al. (2011) Astrocyte elevated gene-1 (AEG-1): A multifunctional regulator of normal and abnormal physiology. Pharmacol Ther 130: 1-8.
97. Lee SG, Kim K, Kegelman TP, Dash R, Das SK, et al. (2011) Oncogene AEG-1 promotes glioma-induced neurodegeneration by increasing glutamate excitotoxicity. Cancer Res 71: 6514-6523.
98. Emdad L, Sarkar D, Lee SG, Su ZZ, Yoo BK, et al. (2010) Astrocyte elevated gene-1: a novel target for human glioma therapy. Mol Cancer Ther 9: 79-88.
99. Hau P, Jachimczak P, Schlaier J, Bogdahn U (2011) TGF-beta2 signaling in high-grade gliomas. Curr Pharm Biotechnol 12: 2150-2157.
100. Schneider T, Sailer M, Ansorge S, Firsching R, Reinhold D (2006) Increased concentrations of transforming growth factor beta1 and beta2 in the plasma of patients with glioblastoma. J Neurooncol 79: 61-65. (Pubitemid 44057419)
101. Zhang D, Jing Z, Qiu B, Wu A, Wang Y (2011) Temozolomide decreases invasion of glioma stem cells by down-regulating TGF-beta2. Oncol Rep 26: 901-908.
102. Eliseeva IA, Kim ER, Guryanov SG, Ovchinnikov LP, Lyabin DN (2011) Y-box-binding protein 1 (YB-1) and its functions. Biochemistry (Mosc) 76: 1402-1433.
103. Fotovati A, Abu-Ali S, Wang PS, Deleyrolle LP, Lee C, et al. (2011) YB-1 bridges neural stem cells and brain tumor-initiating cells via its roles in differentiation and cell growth. Cancer Res 71: 5569-5578.
104. Gao Y, Fotovati A, Lee C, Wang M, Cote G, et al. (2009) Inhibition of Y-box binding protein-1 slows the growth of glioblastoma multiforme and sensitizes to temozolomide independent O6-methylguanine-DNA methyltransferase. Mol Cancer Ther 8: 3276-3284.